Use of class IC antiarrhythmic drugs in patients with structural heart disease and implantable cardioverter defibrillator
ConclusionIn a multicenter cohort of ICD-carriers with SHD, class-IC-AADs were associated with a low rate of pro-arrhythmic effects or cardiovascular mortality. The majority of patients remained free from sustained VA during a follow-up of > 2 years. Further efforts should be made to evaluate the safety of class-IC-AADs in SHD patients receiving contemporary cardiovascular therapy.Graphical abstract
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research
More News: Amiodarone | Arrhythmia | Cardiology | Cardiomyopathy | Cardiovascular | Heart | Heart Disease | Study